Document:

EXHIBIT 10.19

                                AMENDMENT
                                ---------

     This Amendment to License Agreement dated January 1, 1998 (the
"Agreement") by and between Entropin, Inc., a Colorado corporation
("Entropin"), and Dr. James E. Wynn, individually ("Wynn"), is entered by,
between and among Entropin, Wynn and Distinguished Medical Research, Inc.,
a Nevada corporation ("DMR") (collectively, the "Parties") effective this
1st day of August, 1998.

                                RECITALS

     WHEREAS, Wynn desires to assign his rights under the Agreement to DMR;
and,

     WHEREAS, the parties desire to set forth the procedures pursuant to
which services are to be performed by Wynn on behalf of DMR for Entropin
and compensation for such services is to be paid to DMR by Entropin.

     NOW, THEREFORE, for good and valuable consideration the sufficiency of
which is hereby acknowledged, the parties hereby agree:

     1.   ASSIGNMENT.

          1.1  Contemporaneous with the execution of this Agreement, the
parties shall execute the Assignment Agreement and Consent attached as
Exhibit 1.

          1.2  DMR shall be bound by all of the terms and conditions of the
Agreement and this Amendment.

          1.3  DMR and Wynn jointly and severally warrant and represent
that Wynn shall:

               (a)  perform the scope of work set forth in Section 4 of the
               Agreement; and,

               (b)  continue to be bound by all of the terms and conditions
               of the Agreement and this Amendment.

<PAGE>

          1.4  Entropin acknowledges that Dr. James Wynn is a full time
Assistant Dean and Professor at the College of Pharmacy, Medical University
of South Carolina ("MUSC"), and is governed by the outside activities and
conflict of interest provisions of MUSC.  Wynn and DMR jointly and
severally warrant and represent that they are not subject to any
obligations which would limit or restrict the performance of services
hereunder, including but not limited to obligations with respect MUSC.

     2.   PRIOR TECHNICAL KNOWLEDGE.  The definition of Prior Technical
Knowledge set forth in Article I, Section 1.5 of the Agreement is amended
in its entirety as follows:

          1.5   "Entropin Prior Technical Knowledge" refers to knowledge
derived from services conducted at MUSC or the PDC conducted or supervised
directly or indirectly by Dr. Wynn under the New Products Development
Agreement.  Those services included but are not limited to:

          (a) Research leading to the stabilization of the manufacturing
          process of Esterom(R).

          (b) Research leading to reproducing Esterom(R) to establish its
          formulation

          (c) Manufacturing Esterom(R) for animal studies.

          (d) Supervising Phase I Clinical Studies (toxicity) in human
          beings using Esterom(R).

          (e) Supervising the Phase II Clinical Studies of Esterom(R)
          (toxicity and efficacy) at MUSC.

          (f) Completing preliminary research on Esterom(R).

          (g) Developing an assay for benzoyl ecgonine and ecgonine for the
          purposes of indicating the stability of Esterom(R) using a GC/MS
          analytical method as well as an HPLC method for benzoylecgonine.

     3.   DIRECTOR'S AGREEMENT AND CONFIDENTIALITY.  Dr. Wynn acknowledges
that he is bound by the provisions of the Directors' Agreement dated
October 16, 1998, entered into by him and

                                   -2-

<PAGE>

Entropin, in regards to his role and responsibilities as a director of
Entropin.  Dr. Wynn acknowledges that he is bound by the confidentiality
provisions contained within the Agreement, as it relates to his work and
responsibilities on behalf of  DMR for Entropin.

     4.   SERVICES AND PAYMENT.  Services to be performed by DMR to
Entropin shall be on a project-by-project basis.  With respect to each
project, Entropin and DMR shall execute a written work order detailing the
work to be performed and the milestones therefor, up to and including a
completion date.  The work order shall specify the compensation to be paid
for the project and the payment terms therefor; which terms shall include
payment net 30 days from invoice subject to acceptance, and shall otherwise
be commercially reasonable, and usual and customary for transactions of
this type.

     5.   ARBITRATION.  Although Section 12.3 of the Agreement states that
arbitration shall be conducted in Los Angeles, California, and Section 13.4
of the Agreement states that arbitration shall be conducted in Las Vegas,
Nevada, any and all disputes arising under this Agreement shall be subject
to arbitration pursuant to the rules of the American Arbitration
Association and shall be conducted in Denver, Colorado.

     6.   RELATED PARTY TRANSACTION.  Subsequent to execution of the
Agreement, Wynn was appointed to the Board of Directors of Entropin.  He
has become the Scientific Advisor to Entropin and is acting as liaison to
the Board on behalf of the Scientific Advisory Board.  As a result of
serving in these capacities, the Agreement has subsequently become a
related party transaction between Entropin and Wynn.  Accordingly, the
Board has considered the fairness of the terms and conditions of the
Agreement and this Amendment thereto.  The Board has determined that the
terms and conditions are fair and reasonable, and at least as favorable as
obtainable from a third-party capable of performing the services under the
Agreement.

                                   -3-

<PAGE>

     IN WITNESS WHEREOF, the undersigned have entered into this Amendment
as of the date first set forth above.

ENTROPIN, INC.                     DISTINGUISHED MEDICAL
                                             RESEARCH, INC.

By: /s/ HIGGINS D. BAILEY          By: /s/ JAMES E. WYNN
   ------------------------------     ------------------------------
      Higgins D. Bailey, Chairman                       , an officer

Date: 6-5-99                       Date: 6/5/99
     ----------------------------       ----------------------------

                                   /s/ JAMES E. WYNN
                                   ---------------------------------
                                   James E. Wynn, Individually

                                   Date: 4/23/99
                                        ----------------------------

                                   -4-

<PAGE>

Exhibit 1

                         ASSIGNMENT AND CONSENT
                         ----------------------

     THIS ASSIGNMENT of License Agreement dated January 1, 1998 (the
"License Agreement"), by and among Dr. James E. Wynn, hereinafter referred
to as Assignor, and Distinguished Medial Research, Inc., a Nevada
corporation ("DMR"), hereinafter referred to as Assignee, and Entropin,
Inc., a Colorado corporation, hereinafter referred to as the Company.

                               WITNESSETH:

     WHEREAS, the Company contemporaneous herewith is entering into
Amendment to License Agreement with Assignee, in which this Assignment is
incorporated and made a part thereof; and

     WHEREAS, the Company consents to the Assignment of the Agreement to
Assignee by Assignor.

     NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereto agree as
follows:

     1.   ASSIGNMENT.  Assignor hereby assigns to Assignee all of its
right, title and interest in and to the Option Agreement, as amended.

     2.   CONSENT.  Assignee hereby agrees to be bound by the terms and
conditions of the License Agreement, as amended.

     3.   BINDING NATURE.  This Assignment shall be binding upon the
parties and upon each of their successors and assigns.

     IN WITNESS WHEREOF, the parties have executed this Assignment on the
date first above written.

<PAGE>

                                   ASSIGNOR:

                                   By: /s/ JAMES E. WYNN
                                      ---------------------------------

                                   ASSIGNEE:

                                   By: /s/ HIGGINS D. BAILEY
                                      ---------------------------------

                                   ENTROPIN, INC., a Colorado corporation

                                   By: /s/ HIGGINS D. BAILEY
                                      ---------------------------------
                                      Higgins D. Bailey, Chairman

                                   -2-EXHIBIT 10.20

                       WCCS WRAP AROUND AGREEMENT
                       --------------------------

     This Agreement is made and entered into as of this 10th day of
November, 1999, by and between Entropin, Inc., a Colorado corporation
("Entropin") and Western Center for Clinical Studies, Inc., a California
corporation ("WCCS").

                                 PURPOSE

     WHEREAS, Entropin and Therapeutic Management, Inc. entered into a
Contract Research Organization Services Agreement, dated August 11, 1999
("Therapeutic Management Agreement"), whereby Therapeutic Management, Inc.
("CRO") agreed to assist Entropin in the development of, and/or to conduct
Phase IIIA of a multi-center clinical drug evaluation study to research
Entropin's product, Esterom(R) ("Study");

      WHEREAS, Entropin desires to obtain the services of WCCS to act as
its representative in carrying out certain of its responsibilities and
obligations under the Therapeutic Management Agreement; and

     WHEREAS, WCCS possesses the expertise to assume certain of Entropin's
obligations under the Therapeutic Management Agreement;

     NOW THEREFORE, in consideration of the mutual covenants and agreements
contained herein, and for other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged and as set forth
herein, the parties hereby agree as follows:

                                ARTICLE I
              TRANSFER OF RESPONSIBILITIES AND OBLIGATIONS

1.1  UNITED STATES FOOD AND DRUG ADMINISTRATION REGULATIONS.  The Parties
enter into this Agreement for the express purpose of transferring from
Entropin to WCCS the responsibilities and obligations of Entropin to
conduct, coordinate, manage, and/or develop the Study in accordance with
United States Food and Drug Administration ("FDA") regulations set forth in
21 CFR Section 312, Subpart D, as such may be amended from time to time.
Accordingly, Entropin hereby transfers and WCCS hereby assumes the
compliance responsibilities and obligations for the services set forth in
APPENDIX A, attached hereto and made a part hereof, to conduct, coordinate,
manage and/or develop the Study pursuant to the Protocol, as that term is
defined in Article 1.2 (collectively, the "Services").

1.2  PROTOCOL. Prior to the Effective Date, as defined hereafter, the
Entropin protocol entitled: PROTOCOL NO: ESTEROM 99-02-01 VERSION 2.1 "A
STUDY TO DETERMINE THE EFFECTIVENESS AND SAFETY OF TOPICALLY APPLIED EST321
VERSUS VEHICLE IN PATIENTS WITH DECREASED ACTIVE RANGE OF MOTION ASSOCIATED
WITH IMPAIRED SHOULDER FUNCTION" (the "PROTOCOL"), attached hereto as
APPENDIX B and incorporated by reference herein, may be amended as a result
of FDA requests.  Following the Effective Date, WCCS shall (i) modify when
necessary Entropin Protocol in accordance with the Project Specification
Sheet attached hereto as APPENDIX C and incorporated by reference herein;
and, (ii) WCCS

<PAGE>

shall conduct the Study in accordance with the Protocol, as amended or
revised from time to time with WCCS' approval which shall not be
unreasonably withheld.

1.3  ENTROPIN REPRESENTATIVE. WCCS shall act as Entropin's representative
for acceptance of all information, including, without limitation, any and
all reports and/or copies of tables, due and owing from the performance of
the Therapeutic Management Agreement by Therapeutic Management, Inc.  In no
event shall any such information, or any copies thereof, in whole or in
part, be given to any party other than Entropin, without the express prior
consent of Entropin.

                               ARTICLE II
                            RESPONSIBILITIES

2.1  WCCS RESPONSIBILITIES

     A.   PROVISION OF INFORMATION.   WCCS shall provide all necessary
          information to CRO as reasonably required to assure initiation
          and completion of the Study in accordance with APPENDIX G.  In
          addition, WCCS shall provide to Entropin all communications
          received by WCCS from the CRO, FDA or other governmental
          agencies.

     B.   APPROVAL.   WCCS shall approve all copy, layouts, and Study
          elements in a timely fashion so as to allow CRO to meet its
          obligations under the Therapeutic Management Agreement.

     C.   SCOPE OF WORK.   Subject to the provisions of Paragraph 2.4 and
          2.5, WCCS shall perform the services set forth within the Project
          Specification Sheet, as set forth in APPENDIX C, attached hereto
          and incorporated by reference herein.

2.2  ENTROPIN RESPONSIBILITIES

     A.   PROVISION OF INFORMATION.   Entropin shall provide to WCCS all
          communications received by Entropin from the CRO, FDA or other
          governmental agencies.

     B.   SUPPLY OF STUDY DRUG.   Entropin will assure that the Study Drug
          is available on a timely basis and in amounts WCCS deems adequate
          to accommodate the patient treatment period as specified in the
          Protocol.

2.3  TERM.  This Agreement shall commence at such time as the Protocol has
been amended and accepted by the FDA, in accordance with the FDA
modifications requested in FDA correspondence, dated September 13, 1999
("Effective Date"), and remain in full force and effect until such time as
the Services have been completed (the "Term"), unless sooner suspended
pursuant to Article 2.8 or terminated pursuant to Articles 2.5, 2.6 or 2.7.

                                    2

<PAGE>

2.4  EXTENSION OR MODIFICATION OF THE TERM.   Subject to Suspension of the
Term as set forth in Article 2.8, the Term may only be extended or modified
in accordance with a written amendment signed by the Parties as set forth
in Article XX.

2.5  TERMINATION BY ENTROPIN.

     A.   TERMINATION AT WILL.  At any time within three months from the
          date hereof, Entropin may terminate this Agreement at will
          immediately without cause and shall pay WCCS compensation to date
          of termination.  At any time during the remainder of the Term,
          Entropin may terminate this Agreement without cause and shall pay
          WCCS: (1) compensation to date of termination, and (2) a
          termination fee consisting of: (a) forgiveness of the amount of
          fee reduction set forth in paragraph 4.1 of the agreement between
          WCCS and Entropin, dated April 6, 1998, and (b) waiver of that
          portion of the fees previously paid to WCCS in accordance with
          the payment schedule in Appendix E hereto which represents excess
          funds for work and expenses not incurred ("Excess Funds").

     B.   TERMINATION FOR CAUSE.  Entropin shall have the right to
          terminate this Agreement for cause, as defined hereafter, upon
          ten (10) days' written notice to WCCS; for purposes of this
          Agreement, "cause" shall mean conviction of WCCS of a crime
          involving moral turpitude, WCCS' habitual neglect of WCCS' duties
          under this Agreement or theft of Entropin property. Upon
          termination, Entropin's sole obligation to WCCS shall be to pay
          WCCS any equitable pro-rated monies due for work actually
          performed and/or expenses actually incurred up to the effective
          date of termination.  WCCS shall promptly refund to Entropin any
          and all Excess Funds.

     C.   TERMINATION FOR BREACH.  Entropin shall have the right to
          immediately terminate this Agreement in the event WCCS commits a
          material breach hereof and fails to cure such material breach
          within 30 days of receipt of written notice thereof. Upon
          termination, Entropin's sole obligation to WCCS shall be to pay
          WCCS any equitable pro-rated monies due for work actually
          performed and/or expenses actually incurred up to the effective
          date of termination.  WCCS shall promptly refund to Entropin any
          and all Excess Funds.

     D.   TERMINATION OF THERAPEUTIC MANAGEMENT AGREEMENT.  In the event
          that the Therapeutic Management Agreement is terminated for any
          reason, this Agreement may be terminated by Entropin upon 30 days
          written notice to WCCS. Upon termination, Entropin's sole
          obligation to WCCS shall be to pay WCCS any equitable pro-rated
          monies due for work actually performed and/or expenses actually
          incurred up to the effective date of termination.  To the extent
          that such actual costs and expenses shall be less than the total
          monies previously paid to WCCS by or on behalf of Entropin, WCCS
          shall promptly refund to Entropin any and all such excess funds.

                                    3

<PAGE>

     E.   WCCS'S OBLIGATIONS UPON NOTICE OF TERMINATION.  Upon the delivery
          of notice of termination by Entropin, WCCS shall cease the Study.
          WCCS will return to Entropin all Confidential Information (as
          defined in Article IV) and transfer and assign all property and
          materials (including unused materials) in WCCS's possession or
          control that belong to Entropin, including, but not limited to,
          the right, title, and interest in and to the Inventions (as
          described in Article 14.1) and patent applications and patents
          thereon.  Following the receipt of such notice of termination,
          WCCS shall not incur any additional expenses with respect to the
          Study, except those expenses that are documented in detail and
          are necessary in order to terminate the Study.

2.6  TERMINATION BY WCCS

     A.   MATERIAL BREACH.   WCCS shall have the right to immediately
          terminate this Agreement in the event Entropin commits a material
          breach hereof and fails to cure such material breach within 30
          days of receipt of written notice thereof.

     B.   WCCS'S OBLIGATIONS UPON TERMINATION.   Upon WCCS's termination of
          this Agreement, it shall cease the Study.  WCCS will return to
          Entropin all Confidential Information (as defined in Article IV)
          and transfer and assign all property and materials (including
          unused materials) in WCCS's possession or control that belong to
          Entropin, including, but not limited to, the right, title and
          interest in and to the Inventions (as described in Article 14.1)
          and patent application and patents thereon.  Following the notice
          of such termination to Entropin, WCCS shall not incur any
          additional expenses with respect to the Study, except those
          expenses that are documented in detail and are necessary in order
          to terminate the Study.

     C.   ENTROPIN'S OBLIGATIONS UPON TERMINATION.   Upon termination,
          Entropin's sole obligation to WCCS shall be to pay WCCS any
          equitably pro rated monies due and owing it for work actually
          performed and/or expenses actually incurred up to the effective
          date of termination; to the extent that such actual costs and
          expenses shall be less than the total monies previously paid to
          WCCS by or on behalf of Entropin, WCCS shall promptly refund to
          Entropin any and all such excess funds.

2.7  BANKRUPTCY.  Both Parties shall have the right to immediately
terminate this Agreement in the event the other Party makes (i) a general
assignment for the benefit of its respective creditors; (ii) has a
custodian, receiver, or trustee appointed for either it or a substantial
part of its assets; (iii) commences a voluntary proceeding under either the
Federal Bankruptcy Act or any state law relating to insolvency; or (iv) a
court having

                                    4

<PAGE>

jurisdiction over it enters a Decree or Order for Relief in an involuntary
case under any applicable bankruptcy or insolvency law and such Decree or
Order continues unstayed and in effect for a period of 60 days or more.

2.8  DELAY IN TERM.   The Term may be delayed, suspended and/or put on hold
by Entropin for any reason upon 30 days' written notice to WCCS
("Suspension of the Term").  The Term may be suspended by WCCS pursuant to
Article 3.1.  If there is a Suspension of the Term, Entropin agrees WCCS
shall have no obligation to renew performance unless Entropin and WCCS
agree on a modification of WCCS' obligations and compensation as
appropriate because of such Suspension. During such Suspension, WCCS shall
have no obligation to perform services hereunder.

2.9  SURVIVAL.   Neither the expiration or termination of this Agreement
shall relieve the Parties of their respective obligations pursuant to
Articles IV, 5.4, 7.3, 10.2, 10.4, XII, XXI, XXV and XXVII.

                               ARTICLE III
                              COMPENSATION

3.1  TOTAL STUDY COST.  The estimated total cost for the Services (the
"Total Study Cost") is detailed in APPENDIX D attached hereto and made a
part hereof.  Notwithstanding Article 3.3, the Total Study Cost shall not
exceed the estimate for any reason without the prior written approval of
Entropin.  Cost increases greater than 10% of the Total Study Cost will
require an amendment to this Agreement.  In the event the prior written
consent of Entropin is not obtained or an amendment to the Agreement has
not been executed, WCCS will suspend all Services prior to exceeding the
estimated Total Study Cost, unless such suspension would result in risks to
the Study Subjects.

3.2  TOTAL STUDY COST PAYMENT SCHEDULE.   The Total Study Cost shall be
payable in accordance with the terms of this Agreement and APPENDICES D AND
E attached hereto and made a part hereof.

3.3  ENTROPIN-REQUESTED CHANGES TO THE PROTOCOL AND/OR STUDY.     Entropin
reserves the right to request WCCS to perform reasonable, related services
("Additional Services") in addition to the services set forth in APPENDICES
A, C AND D.  Subject to the last sentence of this Article 3.3, in the event
Entropin does request WCCS in writing to perform Additional Services,
Entropin and WCCS shall mutually agree on the cost for such Additional
Services prior to WCCS being obligated to undertake such Additional
Services.  Any costs incurred by WCCS under this Article 3.3, which cause
the Total Study Cost to be exceeded without Entropin's prior written
approval, shall not be reimbursed.  Notwithstanding anything to the
contrary set forth in this Article 3.3, WCCS shall perform without any
increase in the Total Study Cost, Addional Services including, without
limitation, those services necessitated as a result of changes to the Study
and/or Protocol, provided that such Additional Services are, or would have
been, reasonably expected to be within the scope of the Study as determined
by industry standards.

                                    5

<PAGE>

3.4  REDUCTION IN THE TOTAL STUDY COST.     In the event any agreed upon
reduction in either the scope of the Study or amount of Services requested
by Entropin reduces the Total Study Cost such that the total amount
previously paid exceeds the reduced Total Study Cost, the difference shall
be returned to Entropin by WCCS in full at the end of the Term.

3.5  MONITORING/MEETING EXPENSE.  Entropin shall reimburse WCCS for all
monitoring/meeting expenses actually incurred by WCCS in accordance with
Entropin's Reimbursement Policy attached hereto as Appendix F and made part
hereof.  As a prerequisite to reimbursement under this Article, WCCS shall
maintain and have readily available appropriate documentation on file in
accordance with Entropin's Reimbursement Policy which may be audited at any
time upon request by Entropin.

3.6  ADDITIONAL POSTAGE.   Entropin shall be invoiced on a monthly basis
and at WCCS's net costs for all necessary next day mail and/or courier
services related to the administration of the Study.  For expedited
shipments, economy two-day delivery is the preferred method.  WCCS will use
discretion when shipping by Standard Overnight delivery and will use
Priority Overnight delivery only when absolutely necessary.

                               ARTICLE IV
                             CONFIDENTIALITY

     In the course of performance of WCCS' duties, WCCS will receive
confidential information as that term is defined in the Non-Disclosure
Agreement dated April 6, 1998, entered into by and between WCCS and
Entropin, attached hereto as Appendix H and incorporated by reference
herein ("Non-Disclosure Agreement").  Pursuant to the terms of the Non-
Disclosure Agreement, WCCS will not disclose the confidential information
to others, except as expressly authorized by Entropin and will not use this
information directly or indirectly for the benefit of WCCS.

                                ARTICLE V
                     STAFF REQUIREMENTS/WCCS AGENTS

5.1  DEBARMENT CERTIFICATION. WCCS represents and warrants that it did not
and will not use in any capacity the services of any person debarred under
subsections (a) or (b) of Section 306 of the Federal Food, Drug, and
Cosmetic Act, as amended, 21 U.S.C. Section 335a(a) and (b), in connection
with its performance of this agreement.

5.2  AFFILIATES, SUBSIDIARIES, SUBCONTRACTORS, AND CONSULTANTS.   Without
the prior written consent of Entropin, WCCS shall not (i) contract with,
nor permit, anyone other than WCCS employees or CRO employees to perform
the Services or (ii) assign material aspects of the Services, or any
material portions thereof, to any outside investigator, affiliate,
subsidiary, subcontractor, and/or consultant (collectively, "WCCS Agent(s)").

                                    6

<PAGE>

5.3  CHANGE OF STAFF.     Any change in the personnel performing material
Services, or any portion thereof, shall be communicated in writing to
Entropin at least 15 days prior to such change by WCCS.  Such written
communication shall be accompanied by written documents describing the
proposed personnel, including, without limitation, CURRICULUM VITAE;
provided that WCCS shall provide Entropin with any additional materials
concerning such proposed personnel as Entropin shall reasonably request
within three days of such request.  WCCS shall remove and replace any
employee and/or WCCS Agent whose performance and/or qualifications are
deemed unsatisfactory by Entropin (in the sole opinion of Entropin).

5.4  CONFIDENTIALITY AND COMPLIANCE.   WCCS will ensure that every WCCS
Agent approved in accordance with Article 5.2 will (i) execute a
confidentiality agreement containing the same provisions set forth in the
Appendix H; and (ii) adhere to the terms and conditions of this Agreement.
WCCS will provide a copy of all such agreements to Entropin in accordance
with Article XIII hereof following their execution.

5.5  WCCS AGENTS COSTS AND/OR FEES.   WCCS shall bear sole responsibility
for any costs, fees, and/or expenses to be paid to any WCCS Agent;
provided, however, Entropin shall bear sole responsibility for all costs,
fees and/or expenses to be paid to the CRO and such other entities detailed
in Appendix D.

5.6  CRO EMPLOYEE DOCUMENTATION.   WCCS will provide Entropin with a
document created and maintained by WCCS and the CRO within 15 days of the
execution of this Agreement containing the following information with
regard to each WCCS and CRO employee providing material services hereunder:
full name, title, services provided, and sample of employee's initials.
WCCS further agrees that it will provide Entropin with updated versions and
notification of any change in WCCS and/or CRO employees made in accordance
with this Agreement or the Therapeutic Management Agreement.

                               ARTICLE VI
                               TIME TABLE

6.1  TIME SCHEDULE.   The timetable for the Services and the Study is set
forth in APPENDIX G attached hereto and made a part hereof.  Entropin shall
be immediately notified by WCCS, in accordance with Article XIII, of any
anticipated or actual delays with respect to the Services and/or the Study.

                               ARTICLE VII
                               STUDY DRUG

7.1  SUPPLY.   WCCS will assure that the Study Drug and comparative
agent(s), if applicable, and placebo(s), if applicable (collectively
referred to as "Vehicle"), are provided on a timely basis and at no charge
to the CRO in amounts WCCS deems adequate to accommodate the patient
treatment period as specified in the Protocol.

                                    7

<PAGE>

7.2  STUDY DRUG SHIPMENT.   WCCS will assure that all Study Drug and
Vehicle(s), if applicable, shall be shipped to the location(s) and/or
person(s) identified by CRO.

7.3  RETRIEVAL OF UNUSED STUDY DRUG.   WCCS represents and warrants that it
will use its best efforts to (i) retrieve and identify all unused Study
Drug and comparative agent(s), if applicable, and placebo(s), if
applicable, from each investigator; (ii) identify each lot, physician, and
patient number; and (iii) log and record the foregoing information for
Entropin review.

7.4  ADVERSE EVENT REPORTING.

     A.   WCCS AGREEMENTS.   WCCS will enter into an agreement with the CRO
          that the following adverse events will be reported to WCCS
          immediately by telephone from the investigator: (i) those events
          which are defined by the Protocol as "serious", including events
          which (a) result in death, severe or permanent disability,
          cancer, congenital anomaly, or overdose; (b) are considered life-
          threatening; and/or (c) which result in hospitalization or
          prolongs an existing hospitalization; and, (ii) those events
          which are defined by Protocol as "unexpected," meaning any event
          which is not identified in nature, severity, or frequency in the
          investigator brochure.

     B.   REPORTS TO ENTROPIN BY WCCS.   WCCS will report to Entropin any
          unfavorable and unintended sign (including an abnormal laboratory
          finding), symptom, or disease temporally associated with the use
          of the medicinal (investigational) product, whether or not
          related to the medicinal (investigational) product.

     C.   PATIENT TREATMENT BY INVESTIGATOR(S).   Any investigator, if
          properly qualified, shall have the right to provide reasonable
          and customary treatment to any Study Subject who exhibits
          symptoms of an adverse reaction.  Such properly qualified
          investigator shall advise WCCS in advance of such treatment,
          whenever reasonably possible, or as soon thereafter if prior
          notice is not possible.

     D.   PAYMENT OF COSTS.   If in the opinion of the investigator and
          WCCS, the Study Subject's reaction directly resulted from the use
          of the Study Drug, placebo provided in conjunction with the
          Study, if applicable, or other required procedures involved in
          the Study, then Entropin shall reimburse patients for all
          reasonable and customary costs associated with the diagnosis and
          treatment provided, to the extent such costs are not reimbursed
          by medical insurance of Study Subjects.  In the event that a
          suspected adverse reaction is not, in the opinion of the
          investigator and WCCS, Study related, Entropin shall provide
          reimbursement for diagnostic work-up costs only.  Entropin's
          obligation to pay the foregoing costs is limited to incidents when

                                    8

<PAGE>

          the Study Drug was administered (a) in accordance with applicable
          law, accepted medical practice, the Protocol and any other
          written instructions, precautions, and/or indications furnished
          by or on behalf of Entropin; and (b) without negligence,
          recklessness, or willful misconduct or omission of the
          investigator or the Study Subjects.

                              ARTICLE VIII
                     REPRESENTATIONS AND WARRANTIES

8.1  REPRESENTATION AND WARRANTIES OF WCCS

     A.   STAFF AND EXPERTISE.   WCCS represents and warrants that it has
          the facilities, professional, technical, and clerical staff,
          experience and expertise sufficient in quality and quantity to
          perform the Services and the Study pursuant to the Protocol
          within the time frame set forth in APPENDIX G.  Further, WCCS
          represents and warrants that it did not and will not use in any
          capacity the services of any person debarred under subsections
          (a) or (b) of Section 306 of the Federal Food, Drug, and Cosmetic
          Act, as amended, 21 U.S.C. Section 335a (a) and (b), in
          connection with its performance of this Agreement.

     B.   COMPLIANCE WITH LAWS.   WCCS represents and warrants that all the
          Services performed and provided by WCCS, its employees and WCCS
          Agents shall fully comply with all applicable federal, state, and
          local laws, rules and/or regulations.

     C.   INCONSISTENT OBLIGATIONS.   WCCS represents and warrants that the
          responsibilities and obligations assumed by WCCS on behalf of
          Entropin hereunder are not in conflict with any other obligations
          WCCS might have.

     D.   INDUSTRY STANDARDS.   WCCS hereby agrees that it will perform,
          and cause its employees and WCCS Agents to perform, the Services
          in a manner commensurate with the highest professional standards
          applicable to its industry.

     E.   FINANCIAL STABILITY.   WCCS shall at all times during the Term of
          this Agreement have sufficient financial resources to perform its
          obligations hereunder.

8.2  REPRESENTATIONS AND WARRANTIES OF ENTROPIN.

     A.   COMPLIANCE WITH LAWS.   Entropin represents and warrants that all
          Study Drug supplied pursuant to this Agreement shall fully comply
          with all applicable federal, state and local laws, rules and
          regulations.

                                    9

<PAGE>

     B.   INSURANCE.   Entropin has delivered to Buyer information as of
          September 1, 1999, detailing the clinical trial liability
          insurance policies carried by Entropin.

     C.   AUTHORITY   Entropin has full power and authority to execute and
          deliver this Agreement and has taken all requisite corporate
          action to authorize the execution, delivery and performance of
          this Agreement.

     D.   FINANCIAL STABILITY.   Entropin shall at all times during the
          Term of this Agreement have sufficient financial resources to
          perform its obligations for Phase IIIA of the Study.

     E.   OWNERSHIP OF PATENTS.  Entropin has obtained assignments of all
          patents underlying the Study Drug and has no knowledge of
          ownership or proprietary rights by any third person.  Further,
          Entropin has taken the necessary steps to safeguard its
          proprietary technology and confidential information.

                               ARTICLE IX
                               COMPLIANCE

9.1  PERFORMANCE.   WCCS will perform the Services in accordance with the
current state of Good Clinical Practices.  WCCS will also comply with all
federal, state, local laws, rules and regulatory requirements applicable to
its performance under this Agreement.

9.2  COMPLIANCE CHANGES.   In the event currently applicable federal,
state, or local laws, rules and/or regulations are changed or new
applicable laws, rules and/or regulations are promulgated, WCCS shall
comply with such change(s) and/or additions.  In the event that compliance
with such new requirements necessitates change(s) in the Services, WCCS
will submit to Entropin a revised technical and cost proposal for
Entropin's review and acceptance prior to WCCS making any changes in the
Services.  The continuation of the Services shall be subject to Entropin's
written approval of such changes and the related costs.

                                ARTICLE X
                      RECORDS, AUDIT AND INSPECTION

10.1 RECORD INSPECTIONS.   Entropin or its designated representatives shall
have access to, and be permitted to review, during normal business hours
and upon reasonable advance notice during the Term (including any Delay of
the Term in accordance with Article 2.8), all papers, correspondence,
books, records, data, information, instructions, receipts, and/or reports
relating to the Services (collectively, "Records") performed by or on
behalf of WCCS pursuant to this Agreement including, but not limited to,
those Records concerning

                                   10

<PAGE>

the Services which may be either in the possession of WCCS, the CRO or
located at the investigator site(s).  Records shall include Study-related
financial records with respect to monitoring/meeting expenses, payments to
WCCS Agents or CRO Agents and when applicable, investigator Study grant
payments (i.e., honoraria).

10.2 MAINTENANCE OF THE RECORDS.   WCCS shall preserve the Records, without
additional compensation therefor, during the Term and thereafter for a
period of five (5) years (or longer if required by law).  Entropin shall
provide instructions to WCCS with respect to the removal of the Records
from the WCCS and/or CRO facility and shall bear all costs of removal.
Once the Records have been satisfactorily removed in accordance with
Entropin's instructions, Entropin shall be solely responsible for the
storage of Records.

10.3 SITE MONITORING VISITS.   WCCS and/or Entropin's representatives may,
during the Term, visit the CRO's and/or CRO Agents' facilities and
laboratories at reasonable times and with reasonable frequency during
normal business hours to (i) observe the progress of the Study; (ii)
monitor the accuracy and completeness of the Services, including but not
limited to, quality control and assurance; and/or (iii) review the
responsibilities and/or performance obligations of the CRO and/or CRO
Agents.  WCCS will assist Entropin in scheduling such visits and will make
Records and any other relevant information available to Entropin and/or
representatives.

10.4 AUDIT AND/OR INSPECTION.   WCCS shall notify Entropin immediately upon
being notified or becoming aware of any planned, scheduled or ongoing FDA
audit and/or inspection of any study site, WCCS and/or WCCS Agents, the CRO
and/or CRO Agents during the Term and thereafter for a period of five (5)
years.

                               ARTICLE XI
                                INSURANCE

11.1 REQUIRED INSURANCE.   WCCS will, at its own cost and expense, obtain
and maintain in full force and effect, the following insurance during the
term of this Agreement:

     A.   Workers' Compensation Insurance in accordance with the statutory
          requirements of the state in which the Services are to be
          performed;

     B.   Employers Liability Insurance with minimum coverage  of One
          Million Dollars ($1,000,000);

     C.   Comprehensive General Liability Insurance including a products
          liability coverage endorsement, covering all of WCCS' operations
          under this Agreement including broad contractual liability
          coverage, with minimum coverage of Three Million Dollars
          ($3,000,000) per occurrence, and Three Million Dollars
          ($3,000,000) in the aggregate.

                                   11

<PAGE>

11.2 CERTIFICATE(S) OF INSURANCE.   WCCS agrees to provide within 15 days
of execution of this Agreement, an original signed Certificate(s) of
Insurance evidencing all coverage required pursuant to this Article XI.
The Certificate(s) must provide that 30 days' prior written notice of
cancellation will be given to Entropin.

11.3 REQUIREMENTS FOR WCCS AGENTS.   WCCS will not permit any WCCS Agent to
perform Services unless such WCCS Agent is and remains insured in
accordance with the insurance requirements outlined in this Article XI.
WCCS shall indemnify Entropin for any loss suffered by Entropin for the
failure of any WCCS Agent to be so insured.

                               ARTICLE XII
                             INDEMNIFICATION

12.1 ENTROPIN INDEMNIFICATION OF WCCS

     A.   PROPER PERFORMANCE AND STUDY DRUG CLAIMS.   Entropin agrees to
          indemnify, defend and hold harmless WCCS, WCCS Agents, WCCS'
          affiliates and their respective officers, directors and employees
          ("Indemnitee") from and against any loss, damages, claims, suits,
          actions or demands, including but not limited to reasonable
          attorneys' fees, costs of suit, judgments and settlements, which
          Indemnitee becomes legally obligated to pay on a claim made
          against Indemnitee by any party ("Loss") to the extent that such
          Loss (i) is a result of administration of the Study Drug; (ii)
          arises out of the activities or procedures carried out in the
          Services; or (iii) arises out any material violation of this
          Agreement by Entropin; provided that any such Loss to the extent
          it results either directly or indirectly from the following is
          excluded from this Agreement to indemnify and hold harmless (a)
          the negligence or gross negligence of Indemnitee, (b) the willful
          malfeasance or nonfeasance by Indemnitee, (c) any material non-
          compliance or violation by Indemnitee of this Agreement,
          including, but not limited to, Articles IV (Confidentiality), 7.4
          (Adverse Event Reporting), 8.1 (Representations and Warranties of
          WCCS), IX (Compliance) or the Protocol, or (d) any material non-
          compliance or violation by  Indemnitee of any applicable local,
          state, or federal law(s), rule(s), or regulation(s) including,
          but not limited to, applicable FDA regulations and other
          governmental requirements.

     B.   CONDITIONS OF INDEMNITY OBLIGATIONS.  As condition precedent to
          indemnification under Article 12.1 (A), Indemnitee agrees to
          notify Entropin in writing within ten (10) days of Indemnitee
          becoming aware of any claim threatened, asserted, made, brought
          or instituted against it that could or may result in a Loss.
          Whenever the Indemnitee has information from which it may
          reasonably conclude that any incident of bodily injury, sickness,
          disease or death has occurred or will occur (an "Incident") to a
          Study Subject during the Study, Indemnitee shall immediately
          notify Entropin of all pertinent data

                                   12

<PAGE>

          surrounding such Incident.  Indemnitee shall cooperate fully in
          assisting Entropin with respect to gathering information
          concerning the time, place and circumstances of such potential or
          actual claim(s) and in obtaining the names and addresses of the
          injured parties and all available witnesses.  Indemnitee agrees
          to cooperate with and to authorize Entropin to control the
          defense of such claim(s) (including all decisions as to legal
          counsel, litigation, settlement and appeal).  No Indemnitee shall
          compromise or settle any claim(s) without the prior written
          approval of Entropin.

12.2 WCCS INDEMNIFICATION OF ENTROPIN.   In addition to the indemnification
requirements set forth in Article 11.3, WCCS hereby agrees to the following:

     A.   BODILY INJURY OR PROPERTY LOSS.   WCCS agrees to indemnify,
          defend and hold harmless Entropin, Entropin's affiliates and
          their respective officers, directors and employees ("Indemnitee")
          from and against any loss, damages, claims, suits, actions or
          demands, including but not limited to reasonable attorneys' fees,
          cost of suit, judgments and settlements, which Indemnitee becomes
          legally obligated to pay on a claim made against Indemnitee by
          any party ("Loss") to the extent that such Loss results either
          directly or indirectly from any bodily injury sustained,
          including death, and/or for damage to or loss of any property
          incurred during or as a result of WCCS', its officers',
          directors', agents', or employees' or WCCS Agent's acts,
          omissions, and/or performance under this Agreement, to the extent
          such Loss is not indemnified by Entropin pursuant to Article
          12.1.  Notwithstanding anything to the contrary set forth in this
          Article 12.2 (A), to the extent that Entropin has expressly
          directed WCCS and/or the CRO to engage certain investigator(s) to
          perform Services, WCCS shall be relieved of its indemnification
          obligations under this Article 12.2 (A) but only to the extent
          such Loss is a result of the acts and/or omissions of such
          investigator(s).

     B.   BODILY INJURY AND PROPERTY LOSS.   WCCS agrees to indemnify,
          defend and hold harmless Indemnitee from and against any loss,
          damages, claims, suits actions or demands, including but not
          limited to reasonable attorneys' fees, costs of suits, judgments
          and settlements which Indemnitee becomes legally obligated to pay
          on a claim made against Indemnitee by any party ("Loss") to the
          extent such Loss results either directly or indirectly from any
          bodily injury, damage to or loss of any property incurred due to
          WCCS', its officers', directors', agents', or employees' or WCCS'
          Agent's (i) negligence or gross negligence or willful malfeasance
          or nonfeasance; (ii) willful malfeasance or nonfeasance; (iii)
          any material violation of this Agreement, including but not
          limited to, Articles IV (Confidentiality), 7.4 (Adverse Event
          Reporting), 8.1 (Representations and Warranties of WCCS), IX
          (Compliance) or the Protocol; and (iv) material non-compliance or
          violation of any applicable local, state or federal law(s),
          rule(s), or regulation(s), including, but not limited to
          applicable FDA regulations and other governmental requirements.

                                   13

<PAGE>

                              ARTICLE XIII
                                 NOTICES

     Any report or notice required or permitted to be given hereunder shall
be effective when received.  All notices shall be in writing and given
personally or by prepaid certified mail, return receipt requested, or sent
by telex, telegram, expedited delivery service of facsimile transmission
(with written confirmation by certified mail, return receipt requested)
addressed to the Parties at their respective addresses as follows.

If to Entropin:               Entropin, Inc.
                    41926 Oasis Street
                    Indio, CA 92201
                    Attention:  Donald Hunter, Chief Executive Officer
                    Telephone:     (760) 775-8333
                    Fax:           (760) 347-6563

If to WCCS:         Western Center for Clinical Studies, Inc.
                    21550 Oxnard Street, Suite 810
                    Woodland Hills, CA 91367
                    Attention: Roy Azarnoff, COO
                    Telephone:     (818) 340-2323
                    Fax:           (818) 340-3006

                               ARTICLE XIV
                          INTELLECTUAL PROPERTY

14.1 ENTROPIN PROPERTY.   Any and all materials, information, documents,
inventions, discoveries and improvements whether or not patentable, which
during the Term (i) are prepared, made or developed by WCCS its employees
and/or any WCCS Agent; (ii) and/or were conceived, made or reduced to
practice by WCCS, its employees or any WCCS Agent; and/or (iii) as a result
of Confidential Information (collectively, the "Inventions") shall be
promptly disclosed to Entropin and shall be the sole and exclusive property
of Entropin.

     WCCS will, upon request of Entropin, promptly execute and will use its
best efforts to cause its employees and WCCS Agents to execute any and all
applications, assignments or other instruments which Entropin shall
reasonably deem necessary or useful in order to apply for and/or obtain
patent protection worldwide for the Inventions, and/or in order to assign
and convey to Entropin the sole and exclusive right, title and interest in
and to the Inventions, patent applications and patents thereon.  WCCS shall
ensure that its contractual arrangements with its employees and/or WCCS
Agents provide for their automatic assignment to Entropin of all such
Inventions, patent applications and patents.  Entropin

                                   14

<PAGE>

will bear the costs of preparation and filing of all patent applications
with respect to the Inventions.

14.2 PRESERVATION OF ENTROPIN PROPERTY.   All materials and documents
prepared, purchased or furnished by WCCS on Entropin's account in
connection with the Study shall belong to Entropin, and shall be preserved
by WCCS in accordance with Article 10.2 and in compliance with regulatory
requirements for delivery to Entropin upon its request.  Except as set
forth in the Protocol, Entropin retains the title to and exclusive right to
publish all documentation, research data, records, raw data, other work
product, data, and/or results generated with respect to the Services ("Work
Product").  Such Work Product will be retained in the WCCS's archive in
compliance with regulatory requirements and Article 10.2.

14.3 EXPIRATION OR TERMINATION.   Upon the expiration or termination of
this Agreement, WCCS shall transfer, assign and make available to Entropin,
if Entropin so requests, all property and materials in WCCS' possession or
control belonging to Entropin including, without limitation, the right,
title and interest in and to the Inventions and patent applications and
patents thereon.  WCCS shall cooperate in obtaining the consents of third
parties in interest, if any.

                               ARTICLE XV
                       RELATIONSHIP OF THE PARTIES

15.1 NATURE OF RELATIONSHIP.   WCCS agrees that, in its relationship with
Entropin hereunder, it is acting in the capacity of an independent
contractor and that it has no authority to create or assume in Entropin's
name or on Entropin's behalf any obligation, expressed or implied, or to
act or purport to act as Entropin's agent or legally empowered
representative for any purpose whatsoever, except as expressly provided
herein, without Entropin's prior written consent.  Accordingly, WCCS shall
perform the Study as an independent contractor and shall have complete and
exclusive control over its employees and/or WCCS Agents.

15.2 NON-LIABILITY.   Entropin shall not be liable to any third party in
any way for the engagement, obligation, commitment, contract,
representation, transaction or for any negligent act of or omission to act
by WCCS, except as expressly provided in Article XII.

                               ARTICLE XVI
                              FORCE MAJEURE

16.1 EXCUSE.   If the performance or observance of this Agreement by either
Party or if any of either Party's respective obligations under this
Agreement are prevented or delayed by reason of an act of God, civil
commotion, storm, fire, riots, strikes, legal moratorium, war, revolution
or action by government, the Party so affected shall, upon prompt notice of
such cause being given to the other Party, be excused from such

                                   15

<PAGE>

performance or observance to the extent of such prevention or during the
period of such delay provided that (i) the Party so affected shall use its
best efforts to avoid or remove the cause(s) of non-performance and
observance with utmost dispatch, and (ii) notwithstanding any other
provision of this Agreement, the Party so affected may terminate this
Agreement if such delay continues more than 180 days and upon such
termination, such party shall have no further obligations under this
Agreement except for its obligations upon termination as set forth in
Article 12 hereof.

16.2 REPERFORMANCE.   In the event that any part of the Study is rendered
invalid as a result of claiming excuse pursuant to Article 16.1, WCCS
shall, after written authorization from Entropin to proceed and at
Entropin's sole cost and expense, reperform that part of the Study affected
by such claim of excuse.

                              ARTICLE XVII
                               ASSIGNMENT

     Subject to Article 5.2, WCCS shall not, in whole or in part, assign
its interests and/or obligations under this Agreement, including
performance of any monies due hereunder, to any person, firm, partnership,
corporation or other entity (including by operation of law, judicial
process, or otherwise) without the prior written consent of Entropin, which
consent may be withheld for any reason.  Entropin may assign this Agreement
to any of its affiliates (including by operation of law, judicial process
or otherwise) without the prior written consent of WCCS.

                              ARTICLE XVIII
                          NON-WAIVER OF RIGHTS

     No failure or delay on the part of a Party in either exercising or
enforcing any right hereunder will operate as a waiver of, or impair, any
such right.  No single or partial exercise or enforcement of any such right
will preclude any other or further exercise or enforcement thereof or the
exercise or enforcement of any other right.  No waiver of any such right
will have effect unless given in a signed writing.  No waiver of any such
right will be deemed a waiver of any other right hereunder.

                               ARTICLE XIX
                            BURDEN OR BENEFIT

     This Agreement and all the rights, obligations, duties,
representations, warranties and covenants of each Party shall inure to the
benefit, and be the burden of, and shall be binding upon their respective
affiliates, successors (including by operation of law), and lawful assigns,
and other legal representatives.

                                   16

<PAGE>

                               ARTICLE XX
                               AMENDMENTS

     This Agreement may neither be amended nor any of the provisions
contained herein rescinded, altered, or modified except by writing executed
by the Parties.

                               ARTICLE XXI
                     GOVERNING LAW AND JURISDICTION

     It is understood and agreed that no provision of this Agreement shall
be construed so as to be in conflict with the laws of the State of
Colorado.  It is further agreed that this Agreement is deemed to be
consummated in the State of Colorado, and that the terms and provisions of
this Agreement shall be construed and interpreted pursuant to the laws of
Colorado, without regard to the conflict of laws rules or principles
thereof.  The state or federal courts located in the State of Colorado are
the agreed-upon forum for the resolution of all disputes hereunder, and the
Parties, their officers and employees hereby consent to (i) the
jurisdiction and venue of the aforesaid courts for the purpose of resolving
all such disputes; and (ii) service for process by registered mail, return
receipt requested, or any other manner consistent with federal or Colorado law.

     Any dispute arising between WCCS and Entropin concerning this
Agreement or its interpretation shall be resolved by submission to
arbitration in Denver, Colorado in accordance with the rules of the
American Arbitration Association then in effect.  Any award made by such
arbitrators shall be binding and conclusive for all purposes hereof, may
include injunctive relief, and may be entered as a final judgement in any
court of competent jurisdiction.  The costs and expenses of such
arbitration shall be borne in accordance with the determination of the
arbitrators.

                              ARTICLE XXII
                              SEVERABILITY

     In the event any portion of this Agreement shall be held illegal,
void, or ineffective, the remaining portions hereof shall remain in full
force and effect.  If any of the terms or provisions of this Agreement are
in conflict with any applicable statute or rule of law, then such term(s)
or provision (s) shall be deemed inoperative to the extent that they may
conflict therewith and shall be deemed to be modified to conform with such
statute or rule of law.

                              ARTICLE XXIII
                                HEADINGS

     The headings contained in this Agreement are for convenience for
reference only and shall not affect or alter the meaning of effect of any
provision hereof.

                                   17

<PAGE>

                              ARTICLE XXIV
                              COUNTERPARTS

     This Agreement may be executed simultaneously in one or more
counterparts, each of which shall be deemed to be an original, but all of
which together shall constitute one and the same instrument.

                               ARTICLE XXV
                            ENTIRE AGREEMENT

     This Agreement, together with Appendices A, B, C, D, E, F, G and H set
forth all of the promises, agreements, understandings, covenants,
warranties and representations by and among the Parties and there are no
other promises, agreements, understandings, covenants, warranties, or
representations, oral or written, express of implied, between them with
respect to the subject matter addressed herein.  This Agreement, together
with the attached Appendices, is intended by the Parties to be an
integration of any and all prior agreements and understandings, oral or
written, with respect to the subject matter addressed herein.

                              ARTICLE XXVI
                           ATTACHMENTS/ADDENDA

     Any attachment(s) or addenda referred to herein to be delivered and
the acts to be performed at or subsequent to the Effective Date, including,
without limitation, Protocol (collectively, "Items") are incorporated
herein and expressly made a part of this Agreement as fully as though
completely set forth herein, and all references to this Agreement herein or
in any such Items shall be deemed to refer to and include all said Items.

                              ARTICLE XXVII
                          YEAR 2000 COMPLIANCE

     WCCS represents, warrants and covenants to and, for the benefit of,
Entropin that:

     A.   All hardware, software, operating systems, mechanical devices,
electronic devices, and any other components or items of CRO's computer
system which are used to produce reports and data for Entropin's use
(collectively, "CRO's Computer Equipment"), and all data provided to
Entropin under this Agreement shall be "Year 2000 compliant" and shall be
free of bugs, viruses, and errors.  "Year 2000 Compliant" means that all of
CRO's Computer Equipment, and all data provided to Entropin under this
Agreement:

     (i)  Shall be free of bugs, viruses and errors that may materially
adversely affect the performance or operation of CRO's Computer Equipment
on or following January 1, 2000 or cause material delays in the services
(including, but not limited to, reports and data) to be provided by CRO's
to Entropin under this Agreement before and/or after January 1, 2000;

                                   18

<PAGE>

     (ii)  Shall operate in the same manner and will have the same
functionality in all respects before and after January 1, 2000;

     (iii) Shall operate without interruption in all respects from the
effective date of this Agreement continuously though January 1, 2000, and
afterwards;

     (iv)  Shall successfully process without interruption data consisting
of or relating to dates from the date of installation continuously through
January 1, 2000, and afterwards;

     (v)  Shall operate such that all features and functionality containing
or calling on a calendar function, including without limitation, any
function indexed to a CPU or other clock, and any function providing
specific dates or days, or calculating spans of dates or days, shall
record, store, process, provide, and, where appropriate, insert, true and
accurate dates and calculations for dates in spans including and following
January 1, 2000;

     (vi)  Shall have no lesser functionality with respect to records
containing dates both, or either, before or after January 1, 2000, that
with respect to dated prior to January 1, 2000, only;

     (vii)  Shall not crash, fail, cause data to be corrupted, or cause any
of Entropin's hardware or software to crash, fail, or cause data to be
corrupted as a result of operating up to and beyond January 1, 2000, or as
a result of processing data consisting of or relating to dates from the
effective date of this Agreement continuously though January 1, 2000, and
afterwards; and

     (viii)  Has successfully been tested for Year 2000 Compliance as set
forth herein, and as to any greater operating requirements as specified by
the relevant hardware or software manufacturer(s).

     B.   If WCCS discovers or learns at any time subsequent to the
execution of this Agreement that any of WCCS' Computer Equipment or any
data provided to Entropin or to be provided to Entropin under this
Agreement does not comply with paragraph A above ('non-compliant"), WCCS
shall notify Entropin of this fact within ten days of dicovering or
learning of said non-compliance.  WCCS' notification shall set forth, with
specificity, the following:

          (i)  A detailed description of the specific hardware, software,
and/or other components or data that WCCS has discovered or learned are
non-compliant, and the manner in which the are non-compliant;

          (ii)  A detailed description of the problems that will occur on
or after January 1, 2000, as a result of non-compliance; and

                                   19

<PAGE>

          (iii)  A detailed description of the method(s) by which WCCS will
make the non-compliant components or data compliant, and the date by which
WCCS will provide such solutions to Entropin in order to bring the
components or data into compliance.

     C.   If WCCS discovers or learns at any time subsequent to the
execution of this agreement that any of WCCS's Computer Equipment or any
data provided to Entropin or to be provided to Entropin under this
Agreement is non-compliant, WCCS shall cure the non-compliance at WCCS's
sole expense within 30 days of discovering or learning of said non-compliance.
If WCCS fails to cure the non-compliance, in addition to and without waiving
any other rights or remedies provided under the law and/or under this
Agreement, Entropin may terminate this Agreement.

     The Parties hereby execute this Agreement as of the date set forth
above.

Western Center for Clinical Studies, Inc.    Entropin, Inc.

By:_______________________                   By:______________________
     Roy Azarnoff, COO                            Donald Hunter, CEO
Date: 11/26/99                               Date:  12/2/99
     ------------------------                     --------------------

                                   20

<PAGE>

                               Appendix A

                    Transfer of Sponsor's Obligations
                                 to WCCS

         APPENDIX A IS CONFIDENTIAL IN ITS ENTIRETY AND HAS BEEN
            OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

<PAGE>

                               Appendix B

Protocol No: Esterom 99-02-01 Version 2.1

A Study to Determine the Effectiveness and Safety of Topically Applied EST 321

Esterom(R) versus Vehicle in Patients with Decreased Active Range of Motion

Associated with Impaired Shoulder Function

         APPENDIX B IS CONFIDENTIAL IN ITS ENTIRETY AND HAS BEEN
            OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

<PAGE>

                               Appendix C

                       Project Specification Sheet

         APPENDIX C IS CONFIDENTIAL IN ITS ENTIRETY AND HAS BEEN
            OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

<PAGE>

                               Appendix D

                 WCCS - A Clinical Budget for Phase III

    (The attached schedules shall be incorporated with Appendix "D")

         APPENDIX D IS CONFIDENTIAL IN ITS ENTIRETY AND HAS BEEN
            OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

<PAGE>

                               Appendix E

                 WCCS Wrap Around Cost Payment Schedule

         APPENDIX E IS CONFIDENTIAL IN ITS ENTIRETY AND HAS BEEN
            OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

<PAGE>

                               Appendix F

                          CRO/Vendor/Consultant
         Monitoring/Meeting Guidelines and Reimbursement Policy

         APPENDIX F IS CONFIDENTIAL IN ITS ENTIRETY AND HAS BEEN
            OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

<PAGE>

                               Appendix G

                            Study Time Table

         APPENDIX G IS CONFIDENTIAL IN ITS ENTIRETY AND HAS BEEN
            OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

<PAGE>

                               Appendix H

               Non-Disclosure Document dated April 6, 1998

<PAGE>

                        NON-DISCLOSURE AGREEMENT

WHEREAS:

     A.   the undersigned parties contemplate entering into or
participating in one or more transactions, and

     B.   the undersigned parties realize that in the course of developing
and negotiating such commercial transactions, each may disclose to the
other information including, but not limited to, financial data, strategies
and proprietary information (herein referred to as "Confidential
Information").

THEREFORE, in consideration of mutual promises and covenants contained in
this Non-Disclosure Agreement, the undersigned do hereby agree as follows:

     1.   Confidential Information which each party to this Agreement may
disclose to the other is considered within this Non-Disclosure Agreement a
valuable business asset and shall remain the exclusive property of each
such party.

     2.   All information they receive from the other, its agents or
advisors they shall hold in confidence and with the terms and conditions
contained in this Non-Disclosure Agreement.

     3.   They will not use Confidential Information they receive from the
other party to directly or indirectly abrogate or circumvent any right
and/or interest of such party in any manner whatsoever and shall not use
the other party's Confidential Information to enter into or cause a third
party to enter into any investment, acquisition, financial provision,
promotion, project development, product purchase or any other
representation or warranty to the detriment of the interests of the other
party.

     4.   They will, in handling the flow of information from the other,
take all reasonable precautions and exact all necessary obligations to
prevent the use of the information by any party who is not a party to this
Non-Disclosure Agreement to the detriment of the interests of the other party.

     5.   The disclosure of Confidential Information by either party is
made solely for the purposes agreed to by both parties so each party agrees
not to use or authorize the use of such confidential information for any
purpose without the prior consent of the other.

     6.   This Non-Disclosure Agreement shall not restrict the use by
either party of information which is freely available to the public at
large without payment or which either party can prove to have known other
than by disclosure by the other party, their representatives or agents.

                               Page 1 of 2

<PAGE>

     7.   Any dispute or controversy involving this Non-Disclosure
Agreement shall be settled by arbitration in accordance with the Agreement
to which this document is an exhibit.

     8.   This Non-Disclosure Agreement shall inure to the benefit of each
party's successors, transferees, heirs, executors, administrators and
assigns for a period of not less than three years from the date of this
Agreement and shall renew automatically in conformity with the laws of the
State of California.

     9.   This Non-Disclosure Agreement shall be construed in conformity
with the laws of the State of California.

     10.  If any provision of this Non-Disclosure Agreement, or the
application of such provision, entity, or circumstances shall be held
invalid, the remainder of this Non-Disclosure Agreement or the application
of such provision to any person, entity, or circumstances other than those
as to which it is held invalid, shall not be affected thereby.

For Entropin, Inc.                 For Western Center for Clincial Studies, Inc.

/s/ Donald Hunter                  /s/ Roy S. Azarnoff
--------------------------------   -------------------------------------

Date     12/2/99                   Date            11/26/99
--------------------------------   -------------------------------------

                               Page 2 of 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]